Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
As of close of business last night, Citius Pharmaceuticals Inc’s stock clocked out at $1.29, up 25.24% from its previous closing price of $1.03. In other words, the price has increased by $25.24% from its previous closing price. On the day, 5.09 million shares were traded. CTXR stock price reached its highest trading level at $1.33 during the session, while it also had its lowest trading level at $0.995.
Ratios:
To gain a deeper understanding of CTXR’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.06 and its Current Ratio is at 0.37. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
On November 30, 2021, Maxim Group started tracking the stock assigning a Buy rating and target price of $4.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTXR now has a Market Capitalization of 14415105 and an Enterprise Value of 17096298.
Stock Price History:
The Beta on a monthly basis for CTXR is 0.88, which has changed by -0.9170418 over the last 52 weeks, in comparison to a change of 0.11213791 over the same period for the S&P500. Over the past 52 weeks, CTXR has reached a high of $26.25, while it has fallen to a 52-week low of $0.65. The 50-Day Moving Average of the stock is 51.13%, while the 200-Day Moving Average is calculated to be -70.10%.
Shares Statistics:
It appears that CTXR traded 2.17M shares on average per day over the past three months and 2170140 shares per day over the past ten days. A total of 11.17M shares are outstanding, with a floating share count of 10.53M. Insiders hold about 5.74% of the company’s shares, while institutions hold 5.69% stake in the company. Shares short for CTXR as of 1748563200 were 664615 with a Short Ratio of 0.31, compared to 1745971200 on 670558. Therefore, it implies a Short% of Shares Outstanding of 664615 and a Short% of Float of 6.78.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
At present, 1.0 analysts are actively evaluating the performance of Citius Pharmaceuticals Inc (CTXR) in the stock market.The consensus estimate for the next quarter is $0.33, with high estimates of $0.33 and low estimates of $0.33.
Analysts are recommending an EPS of between $1.3 and $1.3 for the fiscal current year, implying an average EPS of $1.3. EPS for the following year is $1.93, with 1.0 analysts recommending between $1.93 and $1.93.
Revenue Estimates
Based on 2 analysts’ estimates, the company’s revenue will be $73.04M in the next fiscal year. The high estimate is $78.29M and the low estimate is $67.78M.
